SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors

被引：51

作者：

Revesz, L ^{[1
]}

Di Padova, FE

Buhl, T

Feifel, R

Gram, H

Hiestand, P

Manning, U

Zimmerlin, AG

机构：

[1] Novartis Pharma AG, Arthritis & Bone Res, CH-4002 Basel, Switzerland

[2] Novartis Pharma AG, Preclin Safety, CH-4002 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2000年 / 10卷 / 11期

关键词：

D O I：

10.1016/S0960-894X(00)00200-6

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The 4-hydroxypiyeridine substituent was found to confer high p38 selectivity devoid of COX-1 affinity, when attached to a series of pyridinyl substituted heterocycles. Pyridinyloxazole 11 showed a promising in vivo profile with bioavailability of 64% and ED50 in rat collagen induced arthritis of 10 mg/kg po bid. In contrast to pyridinylimidazoles such as SE 203580, 11 did not inhibit human cytochrome P450 isoenzymes. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：1261 / 1264

页数：4

共 18 条

[1] Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
Adams, JL
Boehm, JC
Kassis, S
Gorycki, PD
Webb, EF
Hall, R
Sorenson, M
Lee, JC
Ayrton, A
Griswold, DE
Gallagher, TF
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) : 3111 - 3116
[2] Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
[3] Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059 -: SB 203580 also inhibits thromboxane synthase
Börsch-Haubold, AG
Pasquet, S
Watson, SP
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) : 28766 - 28772
[4] OXAZOL-SYNTHESEN AUS ALPHA-HALOGEN-KETONEN .4. FORMAMID-REAKTIONEN
BREDERECK, H
GOMPPER, R
[J]. CHEMISCHE BERICHTE-RECUEIL, 1954, 87 (05): : 700 - 707
[5] Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450
Crespi, CL
Miller, VP
Penman, BW
[J]. ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) : 188 - 190
[6] De Laszlo S. E., 1997, [No title captured], Patent No. [9716442, WO 9716442]
[7] Fitzi K., 1972, [No title captured], Patent No. [DE 2,221,546, 2221546, 2,221.546]
[8] Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSBP kinase
Gallagher, TF
Seibel, GL
Kassis, S
Laydon, JT
Blumenthal, MJ
Lee, JC
Lee, D
Boehm, JC
FierThompson, SM
Abt, JW
Soreson, ME
Smietana, JM
Hall, RF
Garigipati, RS
Bender, PE
Erhard, KF
Krog, AJ
Hofmann, GA
Sheldrake, PL
McDonnell, PC
Kumar, S
Young, PR
Adams, JL
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (01) : 49 - 64
[9] p38 MAPK signalling cascades in inflammatory disease
Herlaar, E
Brown, Z
[J]. MOLECULAR MEDICINE TODAY, 1999, 5 (10): : 439 - 447
[10] p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
Lee, JC
Kassis, S
Kumar, S
Badger, A
Adams, JL
[J]. PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) : 389 - 397

← 1 2 →